Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:DNLI NASDAQ:IBRX NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$568.27M2.382.10 million shs1.20 million shsDNLIDenali Therapeutics$14.19-4.3%$14.60$10.57▼$33.33$2.07B1.231.48 million shs1.60 million shsIBRXImmunityBio$2.60+0.4%$2.55$1.83▼$7.48$2.46B0.37.97 million shs7.70 million shsOCULOcular Therapeutix$12.81+0.3%$11.96$5.78▼$13.85$2.23B1.51.85 million shs1.84 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.26%+2.63%+15.02%+5.68%-68.62%DNLIDenali Therapeutics+1.23%+0.20%+12.10%+1.86%-45.27%IBRXImmunityBio+0.78%+8.37%+4.86%-15.64%-28.45%OCULOcular Therapeutix-2.15%+0.55%+2.32%+46.28%+51.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$568.27M2.382.10 million shs1.20 million shsDNLIDenali Therapeutics$14.19-4.3%$14.60$10.57▼$33.33$2.07B1.231.48 million shs1.60 million shsIBRXImmunityBio$2.60+0.4%$2.55$1.83▼$7.48$2.46B0.37.97 million shs7.70 million shsOCULOcular Therapeutix$12.81+0.3%$11.96$5.78▼$13.85$2.23B1.51.85 million shs1.84 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.26%+2.63%+15.02%+5.68%-68.62%DNLIDenali Therapeutics+1.23%+0.20%+12.10%+1.86%-45.27%IBRXImmunityBio+0.78%+8.37%+4.86%-15.64%-28.45%OCULOcular Therapeutix-2.15%+0.55%+2.32%+46.28%+51.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$19.76157.50% UpsideDNLIDenali Therapeutics 3.12Buy$33.50133.45% UpsideIBRXImmunityBio 3.20Buy$10.75314.26% UpsideOCULOcular Therapeutix 3.00Buy$17.2034.74% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, IBRX, DNLI, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/26/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/14/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $15.008/6/2025OCULOcular TherapeutixScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$22.00 ➝ $20.008/5/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.14N/AN/A$8.17 per share0.94DNLIDenali Therapeutics$330.53M6.35N/AN/A$8.53 per share1.68IBRXImmunityBio$14.74M166.41N/AN/A($0.57) per share-4.55OCULOcular Therapeutix$63.72M34.86N/AN/A$2.01 per share6.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)Latest ARVN, IBRX, DNLI, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.645.64DNLIDenali Therapeutics0.0110.2710.27IBRXImmunityBioN/A4.113.98OCULOcular Therapeutix0.2310.1010.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%DNLIDenali Therapeutics92.92%IBRXImmunityBio8.58%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%DNLIDenali Therapeutics12.50%IBRXImmunityBio76.79%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42073.42 million69.95 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableIBRXImmunityBio590945.26 million219.39 millionOptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionableARVN, IBRX, DNLI, and OCUL HeadlinesRecent News About These Companies137,871 Shares in Ocular Therapeutix, Inc. $OCUL Acquired by Cubist Systematic Strategies LLCSeptember 10 at 3:36 AM | marketbeat.comPolar Asset Management Partners Inc. Lowers Stake in Ocular Therapeutix, Inc. $OCULSeptember 9 at 5:21 AM | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.20 Consensus Price Target from BrokeragesSeptember 9 at 2:47 AM | americanbankingnews.comOcular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comOcular Therapeutix™ to Host Investor Day on September 30, 2025September 8, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. $OCUL Shares Sold by Northern Trust CorpSeptember 8, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comOcular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of CareSeptember 7, 2025 | seekingalpha.comOcular Therapeutix gains amid takeover speculationSeptember 6, 2025 | msn.comAdage Capital Partners GP L.L.C. Raises Holdings in Ocular Therapeutix, Inc. $OCULSeptember 6, 2025 | marketbeat.comPanagora Asset Management Inc. Cuts Position in Ocular Therapeutix, Inc. $OCULSeptember 6, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year High - Here's WhySeptember 5, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Insider Donald Notman Sells 1,066 SharesSeptember 5, 2025 | insidertrades.comLooking At Ocular Therapeutix's Recent Unusual Options ActivitySeptember 4, 2025 | benzinga.comParadigm Biocapital Advisors LP Makes New Investment in Ocular Therapeutix, Inc. $OCULSeptember 2, 2025 | marketbeat.com414,104 Shares in Ocular Therapeutix, Inc. $OCUL Purchased by Nuveen LLCAugust 31, 2025 | marketbeat.comInvesco Ltd. Reduces Holdings in Ocular Therapeutix, Inc. $OCULAugust 29, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,885 SharesAugust 28, 2025 | insidertrades.comAlgert Global LLC Acquires New Stake in Ocular Therapeutix, Inc. $OCULAugust 28, 2025 | marketbeat.comOcular Therapeutix™ to Participate in September Investor and Scientific ConferencesAugust 27, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. $OCUL Shares Sold by Vanguard Group Inc.August 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, IBRX, DNLI, and OCUL Company DescriptionsArvinas NASDAQ:ARVN$7.74 -0.07 (-0.90%) Closing price 04:00 PM EasternExtended Trading$7.77 +0.03 (+0.39%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Denali Therapeutics NASDAQ:DNLI$14.19 -0.63 (-4.25%) Closing price 04:00 PM EasternExtended Trading$14.65 +0.46 (+3.24%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$2.60 +0.01 (+0.39%) Closing price 04:00 PM EasternExtended Trading$2.59 -0.01 (-0.38%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Ocular Therapeutix NASDAQ:OCUL$12.81 +0.04 (+0.31%) Closing price 04:00 PM EasternExtended Trading$12.80 -0.01 (-0.04%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
